Retoxumab and the Mustang

Dr. Gertz: When you're looking to trials that are sponsored by pharma, they're going to design it so they absolutely win. So the real question is, when you give a brute nib, do you need retoxumab at all? Is it adding anything? What is a brute nib Retoxumab versus a bend a Mustang? There's going to be a multi-institutional case series that looks retrospectively at a brute nib based versus bend a Mustang based in a case series. But I think the real holy grail would be, do we have to give BTK inhibitors indefinitely? That would also be a valuable question.